Pimodivir hydrochlorid hemihydrate
Based on 8 publication(s) in Google Scholar
Pimodivir hydrochlorid hemihydrate (VX-787) is an orally bioavailable inhibitor of influenza A virus polymerases through interaction with the viral PB2 subunit.
For research use only. We do not sell to patients.
- CAS No.: 1777721-70-6
- Formula: C20H19F2N5O2.HCl.1/2H2O
- Molecular Weight:444.87
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Pimodivir hydrochlorid hemihydrate
More- NPJ Digit Med. 2025 Nov 21;8(1):712. [Abstract]
- Nucleic Acids Res. 2018 Jan 25;46(2):956-971. [Abstract]
- Cell Rep Med. 2026 Mar 9:102646. [Abstract]
- ACS Infect Dis. 2025 Jun 13;11(6):1437-1447. [Abstract]
- Antiviral Res. 2025 Aug:240:106209. [Abstract]
- Antiviral Res. 2021 Apr:188:105035. [Abstract]
- SLAS Discov. 2024 Jan;29(1):66-76. [Abstract]
- bioRxiv. 2021 Jan 5.
Biological Activity
Chemical Information
-
CAS No. 1777721-70-6
-
Molecular Weight 444.87
-
Formula C20H19F2N5O2.HCl.1/2H2O
-
SMILES
FC1=CN=C2NC=C(C3=NC=C(F)C(N[C@@H]4[C@H](C5CCC4CC5)C(O)=O)=N3)C2=C1.Cl.O.[0.5]
-
Synonyms
VX-787 hydrochlorid hemihydrate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
NPJ Digit Med
Predictive modeling & mechanistic validation of synergistic pimodivir combinations for anti-influenza therapy via PB2cap affinity boost. [Abstract]2025 Nov 21;8(1):712. PMID: 41272280 -
Nucleic Acids Res
Capped RNA primer binding to influenza polymerase and implications for the mechanism of cap-binding inhibitors. [Abstract]2018 Jan 25;46(2):956-971. PMID: 29202182 -
Cell Rep Med
Human liver-derived organoids recapitulate Oropouche virus infection and manifestation, enabling antiviral drug discovery. [Abstract]2026 Mar 9:102646. PMID: 41806841 -
ACS Infect Dis
Development of a Universal Type A Influenza Viral RdRp-Induced Reporter System with Potential for Antiviral Drug Screening. [Abstract]2025 Jun 13;11(6):1437-1447. PMID: 40421776 -
Antiviral Res
High-throughput screening for identification of influenza a inhibitors using a cell-based immunofluorescence assay. [Abstract]2025 Aug:240:106209. PMID: 40484321 -
Antiviral Res
Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir. [Abstract]2021 Apr:188:105035. PMID: 33581212 -
SLAS Discov
2024 Jan;29(1):66-76. PMID: 37925159 -
Purity & Documentation
References
[1]. Smee DF, et al. Activities of JNJ63623872 and GS 4071 against influenza A H1N1pdm and H3N2 virus infections in mice. Antiviral Res. 2016 Dec;136:45-50. [Content Brief]
[2]. Fu Y, et al. JNJ872 inhibits influenza A virus replication without altering cellular antiviral responses. Antiviral Res. 2016 Sep;133:23-31. [Content Brief]
[3]. Boyd MJ, et al. Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors. Bioorg Med Chem Lett. 2015 May 1;25(9):1990-4. [Content Brief]
[4]. Byrn RA, et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother. 2015 Mar;59(3):1569-82. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pimodivir hydrochlorid hemihydrate Related Classifications
HY-12353B Related Classifications
Powered by Bioz